Teva Pharmaceutical/$TEVA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Teva Pharmaceutical
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Ticker
$TEVA
Sector
Primary listing
NYSE
Employees
34,789
Headquarters
Tel Aviv, Israel
Website
TEVA Metrics
BasicAdvanced
$28B
38.84
$0.62
0.70
-
Price and volume
Market cap
$28B
Beta
0.7
52-week high
$25.00
52-week low
$12.47
Average daily volume
12M
Financial strength
Current ratio
1.108
Quick ratio
0.523
Long term debt to equity
235.277
Total debt to equity
235.36
Interest coverage (TTM)
4.27%
Profitability
EBITDA (TTM)
4,571
Gross margin (TTM)
49.34%
Net profit margin (TTM)
4.25%
Operating margin (TTM)
22.29%
Effective tax rate (TTM)
26.44%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
5.45%
Return on equity (TTM)
9.71%
Valuation
Price to earnings (TTM)
38.842
Price to revenue (TTM)
1.631
Price to book
3.79
Price to tangible book (TTM)
-2.18
Price to free cash flow (TTM)
47.339
Free cash flow yield (TTM)
2.11%
Free cash flow per share (TTM)
0.506
Growth
Revenue change (TTM)
0.02%
Earnings per share change (TTM)
-172.09%
3-year revenue growth (CAGR)
3.48%
10-year revenue growth (CAGR)
-1.71%
3-year earnings per share growth (CAGR)
-19.11%
10-year earnings per share growth (CAGR)
-11.36%
What the Analysts think about TEVA
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
Bulls say / Bears say
Teva’s main innovative branded drugs—Austedo, Ajovy, and Uzedy—generated $830 million in Q3 2025 revenue, a 33% year-over-year increase, demonstrating the success of its growth strategy. (Reuters)
Strong performance in North America drove U.S. sales 12% higher in Q3 2025, supporting Teva’s leading position in its largest market. (Reuters)
In Q2 2025, branded drug sales grew 26% compared to a year ago, with Austedo sales up 19%, Ajovy up 31%, and Uzedy surging 120%, highlighting the strength of Teva’s innovative product line. (Reuters)
Global generics sales were flat in Q2 2025, with a decline in the U.S. only offset by growth in Europe, showing ongoing pricing and competitive challenges in Teva’s core business. (Reuters)
Following Q3 2025 results, Teva lowered the top end of its 2025 revenue guidance from $17.2 billion to $17.0 billion, signaling caution due to headwinds in the generics business. (Reuters)
Teva expects to lose about $1 billion in future Revlimid sales because of new generic competitors, presenting a significant revenue risk after 2025. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
TEVA Financial Performance
Revenues and expenses
TEVA Earnings Performance
Company profitability
TEVA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Teva Pharmaceutical stock?
Teva Pharmaceutical (TEVA) has a market cap of $28B as of November 08, 2025.
What is the P/E ratio for Teva Pharmaceutical stock?
The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 38.84 as of November 08, 2025.
Does Teva Pharmaceutical stock pay dividends?
No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Teva Pharmaceutical dividend payment date?
Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Teva Pharmaceutical?
Teva Pharmaceutical (TEVA) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.